The survival rate comparison of non small cell lung carcinoma patients who are given by epidermal growth factor receptor-tyrosin kinase inhibitor and those given by first-line chemotherapy treatment. NMSJ. 2022;6(2):103-115. doi:10.20956/nmsj.v6i2.18857